CompanySYRENasdaqWaltham, MA

Spyre Therapeutics, Inc.

Spyre Therapeutics develops extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F for immunology indications, along with combination programs.

Stories only

SEC EDGAR ClinicalTrials.gov spyre.com

8-KSep 11Latest SEC filing, period to Sep 8

Sep 8Latest story

September 2026

Spyre reports positive Phase 2 SPY003 data, completing proof-of-concept for IBD trio

Sep 8Clinical readoutSPY001 SPY002

August 2026

Spyre reports mixed Phase 2 results for SPY072 in rheumatoid arthritis

Aug 25Clinical readoutSPY002-072 Spyre Therapeutics, Inc.

Spyre Therapeutics registers Phase 2 SKYLIGHT trial of SPY072 in hidradenitis suppurativa

Aug 14Trial updateSPY002-072 Spyre Therapeutics, Inc.

Spyre reports Phase 2 IBD data for SPY001, SPY002, sets Q4 rheumatic readouts

Aug 4Quarterly updateSPY001 SPY002